Residency · Residency · Interventional Radiology

Bland Hepatic Artery Embolization

Concept

Transarterial embolization without chemotherapy or radiation -- uses embolic particles alone to occlude tumor-feeding arteries. Relies purely on ischemic necrosis for antitumor effect. Based on the same physiologic principle as TACE: HCC and hypervascular metastases derive >95% of blood supply from the hepatic artery.

Indications

Hepatocellular Carcinoma

Alternative to TACE for BCLC Stage B HCC. Particularly useful when chemotherapy toxicity is a concern (e.g., borderline liver function). Evidence suggests comparable efficacy to TACE for HCC (see below).

Neuroendocrine Tumor (NET) Liver Metastases

Liver-dominant neuroendocrine metastases are often hypervascular. Bland embolization is effective for symptom control (carcinoid syndrome: flushing, diarrhea) and tumor reduction. May be preferred over TACE in NET due to equivalent outcomes and simpler procedure. Guidelines support embolization (bland or TACE) for liver-dominant symptomatic or progressive NET metastases.

Other Hypervascular Tumors

Ocular melanoma liver metastases. Renal cell carcinoma liver metastases. Sarcoma liver metastases. Castleman disease (hepatic involvement). Hepatic adenoma (symptomatic or at risk of hemorrhage).

Embolic Agents

Embolic Agent Comparison

Microspheres

Calibrated microspheres (Embosphere, Embozene, LC Bead Blank): most commonly used. Available in multiple sizes: 40-120, 100-300, 300-500, 500-700 microns. Smaller beads penetrate more distally into the tumor vasculature (potentially more effective but higher risk of non-target embolization). Larger beads cause more proximal occlusion. Non-degradable (permanent occlusion).

Polyvinyl Alcohol (PVA) Particles

Irregularly shaped particles. Available in various size ranges (150-250, 250-355, 355-500 microns). Less predictable than calibrated microspheres due to irregular shape. Can aggregate and cause proximal occlusion. Historically widely used but largely supplanted by calibrated microspheres.

Gelfoam (Gelatin Sponge)

Pledgets or slurry of absorbable gelatin sponge. Provides TEMPORARY occlusion (resorbed in 2-6 weeks). Used as an adjunct to other embolic agents or for temporary embolization. Lower risk of biliary injury due to temporary nature. Common in the cTACE protocol (Gelfoam after Lipiodol-doxorubicin).

Comparison Considerations

Calibrated microspheres provide the most predictable and reproducible embolization. Smaller particles penetrate more distally (potentially better tumor kill, but higher risk). The optimal particle size for bland embolization is debated.

Bland Embolization vs. TACE for HCC

Evidence

Multiple retrospective studies and meta-analyses: no consistent survival advantage for TACE over bland embolization for HCC. The chemotherapy component in TACE may add toxicity without additional benefit (debated). Prospective studies are lacking: no large RCT directly comparing bland embolization to cTACE or DEB-TACE with survival as primary endpoint. Some argue that bland embolization is simpler, cheaper, and equally effective. Others argue that the chemotherapy in TACE provides additive benefit, especially with drug-eluting beads (sustained local drug release). Current practice: TACE remains the standard of care per guidelines (AASLD, EASL), but bland embolization is a reasonable alternative, particularly for patients with concerns about chemotherapy toxicity.

Technique

Arterial access (femoral or radial). Celiac and SMA arteriography (map anatomy, identify variants). Selective catheterization of the hepatic artery supplying the tumor. Superselective microcatheter placement into the tumor-feeding artery. Slow injection of embolic agent under fluoroscopic guidance. Endpoint: near-stasis or stasis in the feeding artery (pruning of the tumor vasculature). Avoid reflux of particles into non-target territories. Completion angiography to confirm devascularization.

Embolization for Neuroendocrine Liver Metastases

Clinical Context

Liver is the most common site of NET metastases. Carcinoid syndrome symptoms (flushing, diarrhea, bronchospasm) are driven by hepatic tumor burden. Octreotide (somatostatin analog) provides medical symptom control but may not control progressive hepatic disease.

Embolization Approach

Bland embolization is effective and commonly used. Typically staged: right lobe first, left lobe 4-6 weeks later (reduces the risk of hepatic decompensation and carcinoid crisis). Carcinoid crisis risk: massive hormone release during embolization can cause life-threatening hemodynamic instability (hypotension, bronchospasm, flushing). Prophylaxis: octreotide infusion (250-500 mcg/hr IV) starting before the procedure and continuing for 24-48 hours. Have vasopressors and octreotide bolus doses available. Symptom improvement in 70-90% of patients. Median duration of symptom control: 12-18 months before retreatment is needed.

Complications

Post-embolization syndrome: pain, fever, nausea (expected; managed supportively). Hepatic abscess: higher risk with bilioenteric anastomosis (Whipple, hepaticojejunostomy); antibiotic prophylaxis recommended in these patients. Hepatic decompensation: risk increases with poor baseline liver function, large treatment volume, and portal vein compromise. Non-target embolization: gallbladder infarction, GI mucosal ischemia. Biliary injury: ischemic stricture, particularly with repeated treatments. Carcinoid crisis (NET-specific): as described above.

<image>Illustration comparing bland hepatic artery embolization and TACE. Two panels: Left panel shows bland embolization with calibrated microspheres being injected through a microcatheter into tumor-feeding arteries, with a magnified inset showing the microspheres occluding tumor arterioles and causing ischemic necrosis (no drug component). Right panel shows TACE with drug-eluting beads loaded with doxorubicin being injected, with a magnified inset showing the beads releasing chemotherapy while simultaneously occluding the vessel. A comparison table below lists the mechanism, advantages, disadvantages, and evidence for each approach.</image>

<image>Angiographic sequence of bland embolization for neuroendocrine liver metastases. Four panels: (1) Celiac angiogram showing a hypervascular liver with multiple enhancing metastases in both lobes; (2) Selective right hepatic arteriogram showing dense tumor blush from multiple hypervascular metastases; (3) Injection of microspheres with progressive devascularization of the tumor blush; (4) Post-embolization angiogram showing near-complete absence of tumor blush with pruning of distal arterial branches. An inset shows the staged approach: right lobe treated first (session 1), left lobe treated 4-6 weeks later (session 2).</image>

<image>Flowchart for embolization approach to liver-dominant metastatic neuroendocrine tumor. Starting with assessment of hepatic tumor burden and symptoms, branching into symptomatic (carcinoid syndrome) versus asymptomatic but progressive categories. Both lead to hepatic arterial embolization (bland or TACE), with mandatory octreotide prophylaxis noted. Decision points include: staging (right then left), antibiotic prophylaxis for bilioenteric anastomosis, and post-treatment monitoring. Outcome boxes show symptom improvement rates and retreatment timing.</image>

Key Clinical Pearls

Bland embolization is likely as effective as TACE for HCC but lacks definitive prospective RCT evidence -- guidelines still favor TACE as the standard. For NET liver metastases, bland embolization is first-line and highly effective for symptom control; always give octreotide prophylaxis to prevent carcinoid crisis. Calibrated microspheres provide more predictable embolization than irregular PVA particles. Stage treatments when treating extensive bilobar disease to avoid hepatic failure. Patients with bilioenteric anastomosis (Whipple, hepaticojejunostomy) are at high risk for hepatic abscess and require antibiotic prophylaxis. Superselective embolization minimizes damage to normal liver parenchyma and reduces complications. The endpoint is near-stasis in the feeding artery -- complete stasis risks reflux and non-target embolization.

References

• Brown KT et al. Randomized trial of hepatic artery embolization for HCC using doxorubicin-eluting microspheres vs. embolization with microspheres alone. J Clin Oncol 2016
• Defined by the ENETS Consensus Guidelines on NET Liver Metastases Management. Neuroendocrinology 2016
• Defined by the SIR Quality Improvement Guidelines for Hepatic Embolization. J Vasc Interv Radiol 2017
• Defined by the AASLD Practice Guidance on HCC Treatment Selection. Hepatology 2023

Read this lecture as Markdown